An Update on Recent Advances of Photodynamic Therapy for Primary Cutaneous Lymphomas

Liu, Wei-Ting; Wang, Han-Tang; Yeh, Yi-Hsuan; Wong, Tak Wah

doi:10.3390/pharmaceutics15051328

Cited by 7 publications

(5 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The idea of our study was to assess the impact of the PDT on skin cells, fibroblasts, and keratinocytes, to assess its immunomodulatory effect and possible possibilities of its use in inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis. In our experiment, hypericin was chosen as the photosensitizer (PS), whose properties have previously attracted the attention of many researchers [ 31 , 32 , 33 , 34 , 35 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

“…The study population included 169 patients, and, after 6 weeks of treatment, HY–PDT was 49% more effective than placebo after 3 cycles. There were no serious drug-related side effects [ 30 , 31 ]. Additionally, Rook et al confirmed, in a phase II placebo-controlled study, the effectiveness of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis [ 32 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxic and Immunomodulatory Effects of Hypericin as a Photosensitizer in Photodynamic Therapy Used on Skin Cell Cultures

Krupka-Olek,

Bożek,

Czuba

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Determination of the hypericin–photodynamic (HY–PDT) effect on the secretion of cytokines secreted by the skin cells, may be the basis for using the immunomodulatory effect of photodynamic action in the treatment of inflammatory skin diseases. The study aimed to evaluate the cytotoxic and immunomodulatory effects of hypericin (HY) in photodynamic therapy (PDT) performed in vitro on cultures of selected skin cell lines. The study used two human cell lines, primary dermal fibroblast (HDFa) and primary epidermal keratinocytes (HEKa). The MTT test was used to define the metabolic activity of treated cells. Cell supernatants subjected to sublethal PDT were assessed to determine the interleukins: IL-2, IL-8, IL-10, IL-11, IL-19, IL-22, and metalloproteinase 1 (MMP-1). The results confirm the destructive effect of HY–PDT and the immunomodulatory effects of sublethal doses on the selected skin cells, depending on the concentration of HY and the light doses. No statistically significant differences were noted in IL-2 and IL-10 concentration after HY–PDT for HEKa and HDFa lines. After using HY–PDT, the concentration of IL-8, MMP-1, IL-22, and IL-11 significantly decreased in the HEKa line. Moreover, the concentration of IL-19 and MMP-1 significantly decreased in the HDFa line. The concentration of IL-11 in the HDFa line after using only the HY, without the light, increased but decreased after HY–PDT. Our experiment confirmed that HY–PDT has not only a cytotoxic effect but, used in sublethal doses, also presents immunomodulatory properties. These may be an advantage of HY–PDT when used in the treatment of persistent skin inflammation, connected with the release of pro-inflammatory cytokines resistant to conventional treatment methods.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cytotoxic and Immunomodulatory Effects of Hypericin as a Photosensitizer in Photodynamic Therapy Used on Skin Cell Cultures

Krupka-Olek,

Bożek,

Czuba

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…PSs can also transfer energy to triplet oxygen in the ground state ( 3 O 2 ) through a Type II reaction to generate highly reactive singlet oxygen, 1 O 2 . In the end, the reactive species produced during the photodynamic process destroy cancer cells directly through apoptosis, necrosis, or autophagy, as well as indirectly by injuring the tumour vascularity, which causes tumour ischemia [29]. It is important to note that both Type I and Type II reactions can occur at the same time.…”

Section: The Principles Of Photodynamic Therapymentioning

confidence: 99%

Photosensitizers-Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment

et al. 2023

View full text Add to dashboard Cite

Malignant melanoma poses a significant global health burden. It is the most aggressive and lethal form of skin cancer, attributed to various risk factors such as UV radiation exposure, genetic modifications, chemical carcinogens, immunosuppression, and fair complexion. Photodynamic therapy is a promising minimally invasive treatment that uses light to activate a photosensitizer, resulting in the formation of reactive oxygen species, which ultimately promote cell death. When selecting photosensitizers for melanoma photodynamic therapy, the presence of melanin should be considered. Melanin absorbs visible radiation similar to most photosensitizers and has antioxidant properties, which undermines the reactive species generated in photodynamic therapy processes. These characteristics have led to further research for new photosensitizing platforms to ensure better treatment results. The development of photosensitizers has advanced with the use of nanotechnology, which plays a crucial role in enhancing solubility, optical absorption, and tumour targeting. This paper reviews the current approaches (that use the synergistic effect of different photosensitizers, nanocarriers, chemotherapeutic agents) in the photodynamic therapy of melanoma.

show abstract

“…Photodynamic therapy (PDT) utilizing photosensitizing agents (such as 5-aminolevulinic acid [ALA]) irradiated with a specific wavelength of light in the presence of oxygen is being explored in CTCL ( 40 , 41 ). Limiting the use of ALA-PDT in CTCL is the poor tissue penetration of the photosensitizers, though new developments in the use of PDT for CTCL, such as innovative photosensitizers beyond ALA, more effective delivery methods deeper into lymphoma lesions, and novel prepping methods, are ongoing ( 42 ).…”

Section: Advances In Skin-directed Therapiesmentioning

confidence: 99%

Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments

Stuver,

Geller

2023

Front. Immunol.

View full text Add to dashboard Cite

Mycoses fungoides (MF) and Sézary syndrome (SS) are cutaneous T-cell lymphomas that are often challenging to manage given the absence of reliably curative therapies, at times high symptom burden with significant detriment to quality of life, and need for ongoing treatment for disease and symptom control. Recent developments in skin-directed treatments include optimizing the use of existing topical therapies, the introduction of known dermatological agents and treatment modalities for the specific treatment of MF/SS (such as mechlorethamine gel, calcineurin inhibitor creams, and photodynamic therapy), and novel local and topical agents. For advanced disease, dedicated clinical trials have translated to exciting progress, leading to the approval of brentuximab vedotin (2017) and mogamulizumab (2018) for relapsed MF/SS. Additional studies of other active systemic agents, including various cellular therapies, represent further attempts to add to the therapeutic armamentarium in treating MF/SS. In this review, we highlight these recent advancements, ranging from optimization of skin-directed therapies to the introduction of novel systemic agents. We focus on therapies approved in the preceding five years or under investigation in advanced-phase clinical trials.

show abstract

An Update on Recent Advances of Photodynamic Therapy for Primary Cutaneous Lymphomas

Cited by 7 publications

References 76 publications

Cytotoxic and Immunomodulatory Effects of Hypericin as a Photosensitizer in Photodynamic Therapy Used on Skin Cell Cultures

Cytotoxic and Immunomodulatory Effects of Hypericin as a Photosensitizer in Photodynamic Therapy Used on Skin Cell Cultures

Photosensitizers-Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment

Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments

Contact Info

Product

Resources

About